Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Amgen Inc. ($AMGN) announced the results of a late-stage study which showed that its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol. The news is expected to have positive impact on the stock price which is currently trading close to its 52 weeks high of $182.
The company stock has gained 25 percent in the past 12 months while its Year to Date gain stands at 24 percent. Amgen said that the study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period. 

Heat Biologics ($HTBX) stock skyrocketed in the pre-market session as it announced that the company achieved the efficacy endpoint for its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab for the treatment of non-small cell lung cancer. The study also met the expansion criteria to advance into a Phase 2. 
The company stock jumped over 40 percent in the pre-market session, taking its 12 months gains to nearly 14 percent. The stock gained 5 percent this year so far. Heat Biologics CEO said that the company remains focused on enrolling new patients to better characterize the objective response rate, durability of the response and associated immune activity.

 

Mylan NV ($MYL) announced that it has inked a global settlement with Roche and Genentech. The deal pertains to two Herceptin patents ‘213 and ‘415. Under this deal, Mylan will receive global licenses for its trastuzumab product, paving a path for the company to market the products globally. The licenses pertain to all countries except Japan, Brazil and Mexico.  The deal also eliminates further patent litigation expenses associated with Genentech and Roche.

Zynerba Pharmaceuticals ($ZYNE) announced that it has hit its enrollment target for Phase 2 STAR 1   clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The Company also announced that enrollment has completed in the Phase 2 STOP clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.

Radius Health Inc. ($RDUS) announced that the  FDA delayed the potential approval of an osteoporosis drug  being developed by the company. The agency has moved its target approval date for the drug, called abaloparatide, from March 30 to June 30 as it needs more time to review additional information in the application.

 

Northwest Biotherapeutics Inc. ($NWBO) announced inking a new deal with a group of bondholders affiliated with Whitebox Advisors ("Whitebox"), holder of $11 million of NW Bio convertible senior notes. The notes were otherwise due on March 10th. Both the parties have negotiated a time payment approach in line with the Company's development schedule with ballooning periodic payments over the course of coming 4 months.

Great Basin Scientific ($GBSN) announced that its stockholders approved a reverse split of the Company’s common stock at a ratio between 1 for 1,700 and 1 for 2,000 and an increase in the Company’s authorized shares of common stock from 1.5 billion to 3.0 billion.  The exact ratio will be set by the Board of Directors upon the completion of the Financial Industry Regulatory Authority‘s review.

 

Endocyte Inc. ($ECYT) reported a net loss of $11.1 million, or $0.26 per basic and diluted share, for the fourth quarter of 2016, compared to a net loss of $9.8 million, or $0.23 per basic and diluted share for the same period in 2015. The company’s research and development expenses were $8.2 million for the fourth quarter of 2016, compared to $6.4 million for the same period in 2015. its cash, cash equivalents and investments were $138.2 million at December 31, 2016.

TG Therapeutics ($TGTX) reported that its net loss was $23.7 million and $78.3 million for the three and twelve months ended December 31, 2016, respectively, compared to a net loss of $17.6 million and $62.9 million for the three and twelve months ended December 31, 2015, respectively. Its  Research and development (R&D) expenses were $22.3 million and $69.2 million for the three and twelve months ended December 31, 2016, respectively, compared to $15.3 million and $47.7 million for the three and twelve months ended December 31, 2015, respectively. 

Brokerage
Action
Company
Rating
Price Target
Janney Montgomery Scott
Upgrades
Acorda Therapeutics (ACOR)
Neutral -> Buy
$38.00
Noble Financial
Reiterates
Agile Therapeutics (AGRX)
Buy

Goldman Sachs Group
Downgrades
Bioverativ (BIVV)
Conviction-Buy -> Neutral

Goldman Sachs Group
Upgrades
Blueprint Medicines Corp (BPMC)
Neutral -> Buy

HC Wainwright
Reiterates
Cytokinetics (CYTK)
Buy

Goldman Sachs Group
Reiterates
Gilead Sciences (GILD)
Neutral
$68.00
Bank of America Corp
Reiterates
Gilead Sciences (GILD)
Neutral
$76.00 -> $68.19
Jefferies Group LLC
Reiterates
Hologic (HOLX)
Buy
$49.00
Noble Financial
Reiterates
Heat Biologics (HTBX)
Buy

Credit Suisse Group AG
Raises Target
Incyte (INCY)

$38.00
Jefferies Group LLC
Reiterates
Karyopharm Therapeutics (KPTI)
Buy

Gainers (% price change)Last TradeChangeMkt CapDynavax Tech. Corp.DVAX6.38+0.48 (8.08%)245.68MHerbalife Ltd.HLF54.58+2.31 (4.42%)5.11BMediciNova, Inc.MNOV6.23+0.25 (4.18%)217.29MBioDelivery Sciences IntlBDSI2.05+0.05 (2.50%)110.94MEndocyte, Inc.ECYT2.50+0.06 (2.46%)113.59MLosers (% price change)Osiris Therapeutics, Inc.OSIR4.69-0.51 (-9.81%)154.74MVanda Pharmaceuticals IncVNDA14.45-0.50 (-3.34%)642.96MImmunoGen, Inc.IMGN3.64-0.09 (-2.41%)324.06MZogenix, Inc.ZGNX10.55-0.25 (-2.31%)295.78MCuris, Inc.CRIS2.90-0.06 (-2.03%)395.45MMost Actives (dollar volume)Johnson & JohnsonJNJ126.53+0.32 (0.25%)344.03BPfizer Inc.PFE33.98-0.13 (-0.38%)202.60BMerck & Co., Inc.MRK64.75-0.38 (-0.58%)176.99BIncyte CorporationINCY147.87-1.37 (-0.92%)30.28BUnitedHealth Group IncUNH169.87-0.11 (-0.06%)163.47B